Not known Details About BRD4 inhibition by ABBV-744 in cancer research studies
These side effects had been notably milder in comparison with an inhibitor of both of those bromodomains. A detailed molecular Examination also exposed that ABBV-744 preferentially inhibits the expression of Androgen Receptor (AR)-dependent genes. ― Stephen Taylor88 These preclinical studies present paradigms for future clinical trials in AML,